However, Derks et al. [64] proposed LCNEC molecular classification and showed that LCNEC with wild-type RB1 or RB1 mutated is more likely to be treated with chemotherapy for NSCLC. The gene discussed is RB1; the disease is large cell neuroendocrine carcinoma.